tert-butyl 4-[(1RS)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]piperidine-1-carboxylate | 1207438-80-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-[(1RS)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]piperidine-1-carboxylate；tert-butyl 4-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]piperidine-1-carboxylate
• CAS: 1207438-80-9
• 化学式: C₁₈H₂₅ClFNO₃
• 分子量: 357.853
• InChiKey: SJLLPDDMVXFZLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-[(1RS)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]piperidine-1-carboxylate 在 盐酸 、 乙醇 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 0.58h， 生成 4-[(1RS)-1-(3-chloro-4-fluorophenyl)-2-methoxyethyl]piperidine monohydrochloride
  参考文献：
  名称：

  Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds

  摘要：

  A novel triple reuptake inhibitor with low potential of liabilities associated with cationic amphiphilic drug (CAD) was identified following an analysis of existing drugs. Low molecular weight (MW < ca. 300), low aromatic ring count (number = 1) and reduced lipophilicity (ClogP < 3.5) were hypothesized to be key factors to avoid the CAD associated liabilities (CYP2D6 inhibition, hERG inhibition and phospholipidosis). Based on the hypothesis, a series of piperidine compounds was designed with consideration of the common characteristic features of CNS drugs. Optimization of the side chain by adjusting overall lipophilicity suggested that incorporation of a methoxymethyl group could provide compounds with a balance of both potent reuptake inhibition and low liability potential. Compound (S)-3a showed a potent antidepressant-like effect in the mice tail suspension test (MED = 10 mg/kg, p.o.), proportional monoamine transporter occupancies and enhancement of monoamine concentrations in mouse prefrontal cortex. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.025
• 作为产物：
  描述：

  3-氯-4-氟苯乙腈 在 sodium tetrahydroborate 、 硼烷四氢呋喃络合物 、 水 、 氢溴酸 、 sodium methylate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 27.5h， 生成 tert-butyl 4-[(1RS)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]piperidine-1-carboxylate
  参考文献：
  名称：

  Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds

  摘要：

  A novel triple reuptake inhibitor with low potential of liabilities associated with cationic amphiphilic drug (CAD) was identified following an analysis of existing drugs. Low molecular weight (MW < ca. 300), low aromatic ring count (number = 1) and reduced lipophilicity (ClogP < 3.5) were hypothesized to be key factors to avoid the CAD associated liabilities (CYP2D6 inhibition, hERG inhibition and phospholipidosis). Based on the hypothesis, a series of piperidine compounds was designed with consideration of the common characteristic features of CNS drugs. Optimization of the side chain by adjusting overall lipophilicity suggested that incorporation of a methoxymethyl group could provide compounds with a balance of both potent reuptake inhibition and low liability potential. Compound (S)-3a showed a potent antidepressant-like effect in the mice tail suspension test (MED = 10 mg/kg, p.o.), proportional monoamine transporter occupancies and enhancement of monoamine concentrations in mouse prefrontal cortex. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.025

文献信息

• [EN] CYCLIC AMINE COMPOUND<br/>[FR] COMPOSÉ AMINE CYCLIQUE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010016554A1

  公开（公告）日：2010-02-11

  　式（Ｉａ）： （式中、各記号は明細書に記載の通りである。）で表される化合物またはその塩。本発明の化合物は、モノアミン再取り込み阻害活性を有し、うつ病、不安症、注意欠陥・多動性障害、腹圧性尿失禁等の治療・予防薬等として有用である。
• Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds
  作者：Yuji Ishichi、Eiji Kimura、Eiji Honda、Masato Yoshikawa、Takashi Nakahata、Yasuko Terao、Atsuko Suzuki、Takayuki Kawai、Yuuichi Arakawa、Hiroyuki Ohta、Naoyuki Kanzaki、Hideyuki Nakagawa、Jun Terauchi

  DOI：10.1016/j.bmc.2013.05.025

  日期：2013.8

  A novel triple reuptake inhibitor with low potential of liabilities associated with cationic amphiphilic drug (CAD) was identified following an analysis of existing drugs. Low molecular weight (MW < ca. 300), low aromatic ring count (number = 1) and reduced lipophilicity (ClogP < 3.5) were hypothesized to be key factors to avoid the CAD associated liabilities (CYP2D6 inhibition, hERG inhibition and phospholipidosis). Based on the hypothesis, a series of piperidine compounds was designed with consideration of the common characteristic features of CNS drugs. Optimization of the side chain by adjusting overall lipophilicity suggested that incorporation of a methoxymethyl group could provide compounds with a balance of both potent reuptake inhibition and low liability potential. Compound (S)-3a showed a potent antidepressant-like effect in the mice tail suspension test (MED = 10 mg/kg, p.o.), proportional monoamine transporter occupancies and enhancement of monoamine concentrations in mouse prefrontal cortex. (C) 2013 Elsevier Ltd. All rights reserved.